Cell Signaling Technology is proud to partner with the Koch Institute at MIT, Science, and Science Signaling to present the Targeting Cancer Pathways webinar series. These webinars will bring together thought leaders from around the world to share current findings and further cancer research community collaboration.
The last few years have witnessed several breakthroughs in the immuno-oncology space. Treatments that harness the body’s immune system to fight cancer have transitioned from speculation to offering endless possibilities for drug discovery. Of these treatments, therapeutic monoclonal antibodies are positioned at the forefront of the immunotherapy revolution, and the FDA has approved several of these monoclonal antibodies to treat cancer.
We as scientists learn from each success and failure. Sometimes it takes many failures to achieve success. And some discoveries are made with no fanfare, far from the spotlight. Other times, a good day’s work is even sweeter when you realize someone noticed!
Cell Signaling Technology is proud to partner with the Koch Institute at MIT, Science, and Science Signaling to present the Targeting Cancer Pathways webinar series. These webinars bring together thought leaders from around the world to share current findings and further cancer research community collaboration.
This two part webinar features Dr. Li Huei Tsai from the Picower Institute at MIT and CST Development Scientist, Dr. Raphael Rozenfeld. Dr. Tsai discusses how modeling systems can be combined with immunolabeling and imaging techniques to unlock the mystery of Alzheimer's Disease. Dr Rozenfeld describes the rigorous validation procedure our antibodies undergo before being release, with special emphasis placed on our neuroscience portfolio. Check out the abstracts below and then click on the button to watch their exciting presentations.
Topics: Cancer Research
Journal Club: YAP-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer.
The article we have chosen was published in the October 29th, 2015 issue of the journal Nature by Gregorieff et al., from the Lunenfeld Tanenbaum Research Institute and University of Toronto, Ontario Canada. The article is entitled YAP-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer, and focuses on stem cell dynamics within the intestinal epithelium, the most rapidly self-renewing tissue in adult mammals.
Cell Signaling Technology is proud to present the following On-Demand Webinar:
The Use of Highly Validated Antibodies and Optimized ChIP Assays to Analyze Epigenetic Marks and Mechanism in DIsease
Sayura Aoyagi, Ph.D, CST Antibody Validation Scientist
Cancer research is near and dear to our hearts, but so is having a good time. AACR is an annual opportunity to get out of the office and get after both.
Immune cells divide rapidly when mounting an immune response against a pathogen, for example, or when initiating a wound-healing response. To accommodate the increased energy requirements to mount the immune response, these cells may employ metabolic pathways similar to those engaged by cancer cells—pathways such as aerobic glycolysis. This correlation presents the intriguing possibility that understanding immune cell metabolism will provide new and actionable insights into the behavior of tumor cells. In this webinar, our expert speakers will explore how this phenomenon is being studied and describe how it could enable the development of new strategies in the fight against cancer.
While it is well established that DNA damage can increase the risk of cancer, changes to the epigenome or the chromatin architecture are equally important. DNA damage triggers a redistribution of DNA-binding proteins around the site of damage, resulting in localized and temporary alteration of chromatin structure. However, repeated cycles of DNA damage and repair may lead to permanent changes in the epigenome, thereby promoting the onset of diseases such as cancer. This webinar will examine how we may be able to develop effective new therapeutic options for cancer treatment by targeting proteins responsible for chromatin modifications.